Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States.
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Axsome Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AXSM's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AXSM exceeded the US Pharmaceuticals industry which returned 6.7% over the past year.
Return vs Market: AXSM exceeded the US Market which returned 20.1% over the past year.
Price Volatility Vs. Market
How volatile is Axsome Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StAxsome Therapeutics, Inc. (NASDAQ:AXSM) Insiders Increased Their Holdings
2 months ago | Simply Wall StWhat Kind Of Shareholder Appears On The Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shareholder Register?
Is Axsome Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AXSM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AXSM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AXSM is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: AXSM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AXSM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AXSM is overvalued based on its PB Ratio (457.4x) compared to the US Pharmaceuticals industry average (3x).
How is Axsome Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AXSM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AXSM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AXSM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if AXSM's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if AXSM's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AXSM's Return on Equity is forecast to be high in 3 years time
How has Axsome Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AXSM is currently unprofitable.
Growing Profit Margin: AXSM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AXSM is unprofitable, and losses have increased over the past 5 years at a rate of -31.9% per year.
Accelerating Growth: Unable to compare AXSM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AXSM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.4%).
Return on Equity
High ROE: AXSM has a negative Return on Equity (-778.81%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Axsome Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: AXSM's short term assets ($44.2M) exceed its short term liabilities ($18.5M).
Long Term Liabilities: AXSM's short term assets ($44.2M) exceed its long term liabilities ($19.1M).
Debt to Equity History and Analysis
Debt Level: AXSM's debt to equity ratio (289.6%) is considered high.
Reducing Debt: AXSM had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Inventory Level: AXSM has a low level of unsold assets or inventory.
Debt Coverage by Assets: AXSM's debt is covered by short term assets (assets are 2.2x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AXSM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AXSM has less than a year of cash runway if free cash flow continues to reduce at historical rates of -34.4% each year
What is Axsome Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate AXSM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AXSM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AXSM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AXSM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AXSM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Herriot Tabuteau (51yo)
Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer and Chairman since January 2012. Dr. Tabuteau serves as President at Axsome Therapeutics, ...
CEO Compensation Analysis
Compensation vs Market: Herriot's total compensation ($USD1.06M) is below average for companies of similar size in the US market ($USD4.89M).
Compensation vs Earnings: Herriot's compensation has been consistent with company performance over the past year.
|CFO & Principal Accounting Officer||1.8yrs||US$687.98k||0.11% $3.7m|
|Senior Vice President of Operations & Secretary||4.3yrs||no data||no data|
|Senior Vice President of Clinical Development & Medical Affairs||2.4yrs||no data||no data|
|Chief Commercial Officer||0.5yrs||no data||no data|
|Director of Finance||0yrs||no data||no data|
Experienced Management: AXSM's management team is considered experienced (2.4 years average tenure).
|Lead Director||0yrs||US$99.38k||0.44% $14.8m|
|Independent Director||2.7yrs||US$94.56k||no data|
|Independent Director||5.2yrs||US$88.38k||0.019% $633.4k|
|Independent Director||5.2yrs||US$80.88k||1.83% $61.0m|
Experienced Board: AXSM's board of directors are considered experienced (5.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.8%.
Axsome Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Axsome Therapeutics, Inc.
- Ticker: AXSM
- Exchange: NasdaqGM
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.330b
- Shares outstanding: 36.81m
- Website: https://www.axsome.com
Number of Employees
- Axsome Therapeutics, Inc.
- 200 Broadway
- 3rd Floor
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AXSM||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Nov 2015|
|19X||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2015|
|0HKF||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Nov 2015|
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. The company is also developing AXS-07, which is in Phase III clinical trial for the treatment of migraine; AXS-12 that is in Phase II clinical trial for the treatment of in narcolepsy; AXS-09, which has completed Phase I clinical trial for the treatment of various CNS disorders; and AXS-02, which is in Phase III clinical trial for the treatment of the pain of knee osteoarthritis associated with bone marrow lesions, and for the treatment of chronic low back pain associated with Modic changes. In addition, it is developing AXS-06 that has completed Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastrointestinal ulcers. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. The company was founded in 2012 and is based in New York, New York.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/18 01:03|
|End of Day Share Price||2020/02/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.